Genmab A/S (NASDAQ:GMAB) Earns Buy Rating from HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating restated by HC Wainwright in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $50.00 price objective on the stock. HC Wainwright’s target price would suggest a potential upside of 138.44% from the stock’s current price.

Other equities research analysts have also recently issued research reports about the stock. BMO Capital Markets reiterated an “outperform” rating and set a $48.00 price target (up previously from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Finally, Redburn Atlantic began coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They issued a “buy” rating on the stock. Three investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Stock Down 3.8 %

NASDAQ:GMAB opened at $20.97 on Thursday. The company’s 50 day moving average price is $21.07 and its 200-day moving average price is $23.98. Genmab A/S has a 52 week low of $19.85 and a 52 week high of $31.88. The stock has a market cap of $13.88 billion, a price-to-earnings ratio of 20.36, a PEG ratio of 0.59 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 EPS for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The firm had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter in the previous year, the company earned $0.47 EPS. As a group, sell-side analysts anticipate that Genmab A/S will post 1.28 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in GMAB. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% in the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after acquiring an additional 1,051 shares during the period. R Squared Ltd bought a new position in Genmab A/S in the fourth quarter worth approximately $93,000. Blue Trust Inc. raised its position in Genmab A/S by 892.0% in the third quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after acquiring an additional 3,880 shares during the period. Allspring Global Investments Holdings LLC raised its position in Genmab A/S by 43.6% in the third quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock worth $113,000 after acquiring an additional 1,413 shares during the period. Finally, Benjamin F. Edwards & Company Inc. raised its position in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares during the period. 7.07% of the stock is currently owned by institutional investors.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.